Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice

Journal of Neural Transmission

Volumn 108, Issue 2, 2001, Pages 167-187

  Fredriksson, A ^a   Danysz, W ^a   Quack, G ^a   Archer, T ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Acute; Amantadine; C57 BL 6 mice; Chronic; Co administration; L Dopa 5 mg kg 20 mg mg; Memantine; MK 801; Motor fluctuations; MPTP hypokinesia locomotion; Rearing; Synergism restoration

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; DIZOCILPINE; DOPAMINE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERANCE; HYPOKINESIA; LOCOMOTION; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REARING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMANTADINE; ANIMALS; ANTIPARKINSON AGENTS; DIZOCILPINE MALEATE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MALE; MEMANTINE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; RECOVERY OF FUNCTION;

EID: 0034938563     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170086     Document Type: Article

References (50)

1. Effects of acute/chronic, subthreshold/threshold doses of L-Dopa in MPTP-treated mice. I. Influence of competitive and noncompetitive NMDA antagonists
2. Dopaminergic-glutamatergic balance in the forebrain: Functional studies of movement disorders in rats and mice
3. Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: Inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects
4. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease
5. Amantadine therapy in parkinsonism
6. Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms
7. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism
8. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? - Case of amantadine and memantine
9. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies
10. NMDA receptor blockade reverses motor response alterations induced by levodopa
11. Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat
12. MPTP-induced behavioural and biochemical deficits: A parametric analysis
13. MPTP-induced hypoactivity in mice: Reversal by L-dopa
14. Effect of the competitive NMDA antagonist, CGP 40116, and a low dose of L-Dopa on the motor activity deficit of MPTP-treated mice
15. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice
16. Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub-/suprathreshold doses of L-Dopa upon motor behaviour of MPTP-treated mice
17. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: Effects of glutamate antagonists
18. Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801
19. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats
20. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease
21. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse
22. L-dopa in Parkinsonism and the influence of previous thalamotomy
23. Dopamine agonists potentiate antiakinetic effects of competitive NMDA-antagonists in monoamine-depleted mice
24. Amantadine attenuates response alterations resulting from repetitive L-DOPA treatment in rats
25. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats
26. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
27. Effect of amantadine on some psychomotor performances in Parkinsonism. A double blind study
28. Dopamine/glutamate interactions in Parkinson's disease
29. MPTP neurotoxicity: An overview and characterization of phases of toxicity
30. Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: Mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists
31. Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: Potential antiparkinsonian activity
32. Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: Relationship with c-fos expression
33. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and L-DOPA administration
34. Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride
35. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade
36. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
37. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine
38. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
39. Behavioural pharmacology of glutamate receptors in the basal ganglia
40. Amantadine and motor fluctuations in chronic Parkinson's disease
41. Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats
42. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
43. Further studies on the mode of action of amantadine
44. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: A model for Parkinson's disease
45. Synergistic interactions between the NMDA antagonist dizocilpine and the preferential dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 with regard to locomotor stimulation in monoamine-depleted mice
46. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
47. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
48. Dissociation between biochemical and behavioral recovery in MPTP-treated mice
49. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist